Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee, USA.
Cancer. 2024 Dec 15;130(24):4188-4199. doi: 10.1002/cncr.34628. Epub 2024 Sep 30.
Comprehensive biomarker testing is a crucial requirement for the optimal treatment of advanced-stage non-small cell lung cancer (NSCLC), with emerging relevance in the adjuvant treatment setting. To advance its goal of ensuring optimal therapy for persons diagnosed with lung cancer, the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) held The Summit on Optimizing Lung Cancer Biomarkers in Practice in September 2020 to align its partners toward the goal of ensuring comprehensive biomarker testing for all eligible patients with NSCLC. The ACS NLCRT's Strategic Plan for Advancing Comprehensive Biomarker Testing in NSCLC, a product of the summit, comprises actions to promote comprehensive biomarker testing for all eligible patients. The approach is multifaceted, including policy-level advocacy and the development and dissemination of targeted educational materials, clinical decision tools, and guides to patients, physicians, and payers aimed at ameliorating barriers to testing experienced by each of these groups. PLAIN LANGUAGE SUMMARY: The ACS NLCRT works to improve care for patients with lung cancer. The ACS NLCRT supports comprehensive biomarker testing as essential to determine treatment options for all eligible patients with non-small cell lung cancer. Many factors lead to some patients not receiving optimal biomarker testing. The ACS NLCRT held a collaborative summit and developed a strategic plan to achieve and promote comprehensive biomarker testing for all patients. These plans include developing educational materials and physician tools and advocating for national policies in support of biomarker testing.
全面的生物标志物检测是晚期非小细胞肺癌（NSCLC）最佳治疗的关键要求，在辅助治疗环境中具有新兴的相关性。为了实现为肺癌患者提供最佳治疗的目标，美国癌症协会国家肺癌圆桌会议（ACS NLCRT）于 2020 年 9 月举办了“优化实践中的肺癌生物标志物峰会”，旨在使合作伙伴达成目标，为所有符合条件的 NSCLC 患者提供全面的生物标志物检测。峰会的产物——《ACS NLCRT 推进 NSCLC 全面生物标志物检测战略计划》包括促进所有符合条件的患者进行全面生物标志物检测的行动。该方法是多方面的，包括政策层面的倡导以及为每个群体开发和传播有针对性的教育材料、临床决策工具和患者、医生和支付方指南，以改善这些群体在检测方面遇到的障碍。
简而言之：ACS NLCRT 致力于改善肺癌患者的护理。ACS NLCRT 支持全面的生物标志物检测，这是确定所有符合条件的非小细胞肺癌患者治疗方案的必要条件。许多因素导致一些患者无法接受最佳的生物标志物检测。ACS NLCRT 举办了一次合作峰会，并制定了一项战略计划，以实现并促进所有患者的全面生物标志物检测。这些计划包括开发教育材料和医生工具，并倡导支持生物标志物检测的国家政策。
